EBUS-TBNA Versus EBUS-TBNB
Launched by ROYAL BROMPTON & HAREFIELD NHS FOUNDATION TRUST · Nov 7, 2011
Trial Information
Current as of August 11, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Scheduled for EBUS-TBNA as part of clinical care
- • Lymph nodes larger than 10mm in diameter
- • Age \> 18 years
- • Able to provide written informed consent
- Exclusion Criteria:
- • Contraindications for needle or forceps biopsy (e.g. coagulopathy, anticoagulation, thrombocytopenia)
- • Inability to obtain informed consent
About Royal Brompton & Harefield Nhs Foundation Trust
Royal Brompton & Harefield NHS Foundation Trust is a leading specialist healthcare provider in the United Kingdom, renowned for its expertise in cardiothoracic medicine and respiratory care. Committed to advancing clinical research and improving patient outcomes, the Trust conducts a diverse range of clinical trials aimed at exploring innovative treatments and therapies. With a multidisciplinary team of clinicians and researchers, the Foundation Trust fosters a collaborative environment that prioritizes patient safety and ethical standards, contributing significantly to the global body of medical knowledge and enhancing the quality of care for patients with complex health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
London, , United Kingdom
Heidelberg, , Germany
Patients applied
Trial Officials
Zaid Zoumot, MBBS, MRCP, MSc
Study Director
Royal Brompton Hospital NHS Foundation Trust, Chelsea and Westminster Hospital NHS Fundation Trust
Pallav L Shah, MD, FRCP
Principal Investigator
Royal Brompton Hospital NHS Foundation Trust, Chelsea and Westminster Hospital NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials